Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Avita Medical ( (RCEL) ).
On October 16, 2025, AVITA Medical announced the departure of CEO James Corbett and the appointment of Cary Vance as Interim CEO. Vance, who has extensive experience in the healthcare industry, will also continue as Chairman of the Board. The company expects third-quarter revenue to be approximately $17 million and is in discussions with OrbiMed to redefine future financial covenants. The Board plans to engage an executive search firm to find a permanent CEO, considering both internal and external candidates, including Vance.
The most recent analyst rating on (RCEL) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.
Spark’s Take on RCEL Stock
According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.
Avita Medical’s overall stock score is primarily impacted by its financial instability, with negative equity and ongoing losses being major concerns. Technical indicators suggest weak momentum, and the valuation is unattractive due to a negative P/E ratio. While the earnings call and corporate events provide some positive outlook, they are insufficient to significantly improve the overall score.
To see Spark’s full report on RCEL stock, click here.
More about Avita Medical
AVITA Medical is a leading therapeutic acute wound care company known for its transformative solutions aimed at optimizing wound healing and accelerating patient recovery. The company’s flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing a patient’s own skin to create Spray-On Skin Cells for improved clinical outcomes. AVITA Medical also holds exclusive rights to market and distribute PermeaDerm and Cohealyx in the U.S., with international approvals for the RECELL System in Europe, Australia, and Japan.
Average Trading Volume: 636,025
Technical Sentiment Signal: Sell
Current Market Cap: $143.2M
For an in-depth examination of RCEL stock, go to TipRanks’ Overview page.